[1]孙红,喻乔,毛谷平,等.长链非编码RNA TUG1在骨肉瘤中的发生机制—系统回顾和荟萃分析[J].中华老年骨科与康复电子杂志,2020,(01):56-61.[doi:10.3877/cma.j.issn.2096-0263.2020.01.011]
 Sun Hong,Yu Qiao,Mao Guping,et al.The role and prognostic value of long noncoding RNA TUG1 in human osteosarcoma: A systematic review and meta-analysis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2020,(01):56-61.[doi:10.3877/cma.j.issn.2096-0263.2020.01.011]
点击复制

长链非编码RNA TUG1在骨肉瘤中的发生机制—系统回顾和荟萃分析()
分享到:

中华老年骨科与康复电子杂志[ISSN:1674-3911/CN:11-9292/R]

卷:
期数:
2020年01期
页码:
56-61
栏目:
Meta分析
出版日期:
2020-02-05

文章信息/Info

Title:
The role and prognostic value of long noncoding RNA TUG1 in human osteosarcoma: A systematic review and meta-analysis
作者:
孙红1喻乔2毛谷平3杨鹏4吴信1宁旭1杨华1
550004 贵阳,贵州医科大学附属医院骨科1;550018 贵阳,贵黔国际总医院骨科2;510080 广州,中山大学附属第一医院关节外科3;550004贵阳,贵州医科大学临床医学院4
Author(s):
Sun Hong1 Yu Qiao2 Mao Guping3 Yang Peng4 Wu Xin1 Ning Xu1 Yang Hua1
1Department of Orthopaedics, Affiliated Hospital of Guizhou Medical University Guiyang 550004, China; 2International General Hospital of Guiqian, Guiyang 550018, China;3Department of Joint Surgery, The First Affiliated Hospital of Sun Yat-sen University;4Department of Clinical Medical College, Guizhou Medical University Guiyang 550004, China
关键词:
TUG1长链非编码RNA 骨肉瘤 预后 meta分析
Keywords:
TUG1 long noncoding RNA human Osteosarcoma Prognosis Meta-analysis
DOI:
10.3877/cma.j.issn.2096-0263.2020.01.011
文献标志码:
A
摘要:
目的 本研究旨在系统回顾长链非编码RNA TUG1(lncRNA TUG1)在骨肉瘤发生、发展中的机制,以及探讨TUG1在评估骨肉瘤患者预后中的价值。方法 系统检索PubMed、Embase、Web of Science、CochraneLibrary、中国知网(CNKI)和万方医学数据库,收集TUG1与骨肉瘤发生及预后的相关文献。系统回顾TUG1在骨肉瘤发生、发展中的机制,并采用Stata12 软件(Stata公司,美国)对TUG1与骨肉瘤患者预后的相关性进行meta分析。结果 目前的研究表明,TUG1主要通过发挥竞争性内源RNA(competing endogenous RNA)效应调控骨肉瘤细胞增殖、凋亡和侵袭等过程,涉及通路包括AKT信号通路和Wnt/β-catenin信号通路。本研究共纳入4篇文献进行meta分析,共244例骨肉瘤患者。TUG1表达升高的骨肉瘤患者总体生存率低于TUG1表达降低的骨肉瘤患者(OR=1.921,95% CI:1.361,2.712,P=0.000)。不仅如此,骨肉瘤患者组织中TUG1表达升高往往提示肿瘤具有更大的体积(OR=4.084,95% CI:2.313,7.211,P=0.000)、较高的临床分级(OR=0.247,95% CI:0.133,0.539,P=0.000)和更早期远处转移(OR=1.943,95% CI:1.130,3.339,P=0.016)。然而,其与患者性别(OR=1.055,95% CI:0.620,1.793,P=0.844)和肿瘤发生部位(OR=0.806,95% CI:0.424,1.530,P=0.509)无显著相关性。结论 长链非编码RNATUG1与骨肉瘤发生、发展密切相关。不仅如此,TUG1表达升高提示骨肉瘤患者不良临床预后,其可能是一种评估骨肉瘤患者预后的生物学标志物。
Abstract:
Objective This study aimed toinvestigate the underlying mechanisms, and the prognostic value of long non coding RNA taurine-upregulated gene 1 (lncRNA, TUG1)inthe development and progression of osteosarcoma. Methods PubMed, Embase, Web of Science, Cochrane Library, ChinaNational Knowledge Internet (CNKI) and Wanfang database were systematically searched for the relevant literature of TUG1 in the development and prognosis of osteosarcoma. STATA12 (Stata Corp, College Station, Texas) was used to estimate pooled effects and the heterogeneity among studies. Results Current studies indicated that TUG1 regulates the proliferation, apoptosis, and invasion by acting as a ceRNA. The underlying mechanisms include AKT and Wnt/β-catenin signal pathways. Four records with a total of 244 osteosarcoma patients were enrolled in this study. The pooled results showed that the patients with high TUG1 expression had shorter overall survival (OS) compared to the patients with low TUG1 expression (OR=1.921, 95% CI: 1.361, 2.712, P=0.000). Moreover, elevated TUG1 expression was associated with advanced tumor size (OR=4.084, 95% CI: 2.313, 7.211, P=0.000), clinical stage (OR=0.258, 95%CI: 0.098, 0.682, P=0.006), and early distant metastasis (OR=1.943, 95% CI: 1.130, 3.339, P=0.016). Nevertheless, high TUG1 expression was not related to gender (OR=1.055, 95% CI: 0.620, 1.793, P=0.844) and anatomical dislocation (OR=0.806, 95% CI: 0.424, 1.530, P=0.509). Conclusions LncRNA TUG1 plays an important role in the molecular mechanisms of osteosarcoma. Elevated TUG1 expression indicates poor OS and clinical parameters in patients undergoing osteosarcoma, which may be used as a moderate prognostic biomarker in human osteosarcoma.

参考文献/References:

1 Rickel K, Fang F, Tao JN. Molecular genetics of osteosarcoma [J]. Bone, 2017, 102(SI): 69-79.2 Miller BJ, Gao YB, Duchman KR. Socioeconomic measures influence survival in osteosarcoma: an analysis of the National Cancer Data Base [J]. Cancer Epidemiol, 2017, 49(8): 112-117.3 Smolle MA, Pichler M. The Role of Long Non-Coding RNAs in Osteosarcoma[J]. Noncoding RNA, 2018,4(1):7.4 孙红, 张志奇, 傅明. 长链非编码RNA在骨关节炎与骨肿瘤领域的研究进展 [J]. 中国骨与关节杂志, 2016, 5(5): 397-400.5 Li JP, Liu LH, Li J, et al. Microarray expression profile of long noncoding RNAs in human osteosarcoma [J]. Biochem Biophys Res Commun, 2013, 433(2): 200-206.6 Zhang Q, Geng PL, Yin P, et al. Down-regulation of long non-coding RNA TUG1 inhibits osteosarcoma cell proliferation and promotes apoptosis [J]. Asian Pac J Cancer Prev, 2013, 14(4): 2311-2315.7 Wang HP, Yu YZ, Fan SX, et al. Knockdown of long noncoding RNA TUG1 inhibits the proliferation and cellular invasion of osteosarcoma cells by sponging miR-153 [J]. Oncol Res, 2018, 26(5): 665-673.8 Wang Y, Yang T, Zhang Z, et al. Long non-coding RNA TUG1 promotes migration and invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells [J]. Cancer Sci, 2017, 108(5): 859-867.9 Li G, Liu KY, Du XH. Long Non-Coding RNA TUG1 promotes proliferation and inhibits apoptosis of osteosarcoma cells by sponging miR-132-3p and upregulating SOX4 expression [J]. Yonsei Med J, 2018, 59(2): 226-235.10 Young TL, Matsuda T, Cepko CL. The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina [J]. Curr Biol, 2005, 15(6): 501-512.11 Wang QL, Chen Q. Role of taurine upregulated gene 1 as a predictor of poor outcome in osteosarcoma [J]. J Cancer Res Ther, 2018, 14(2): S405-S409.12 Ma B, Li M, Zhang L, et al. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma [J]. Tumor Biology, 2016, 37(4): 4445-4455.13 Yu X, Hu L, Li SY, et al. Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1 alpha via miR-143-5p [J]. Cell Death Dis, 2019, 10(4): 280.14 Hu TZ, Fei ZH, Su HF, et al. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling [J]. Toxicol Appl Pharmacol, 2019, 371(5): 55-62.15 Han XF, Yang YM, Sun YJ, et al. LncRNA TUG1 affects cell viability by regulating glycolysis in osteosarcoma cells [J]. Gene, 2018, 674(10): 87-92.16 Xie CH, Chen B, Wu B, et al. LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis [J]. Biomed Pharmacother, 2018, 97(1): 1645-1653.17 Cao JQ, Han XY, Qi X, et al. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via mild-144-3p [J]. Int J Oncol, 2017, 51(4): 1115-1123.18 Yang GH, Zhang C, Wang N, et al. miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and suppresses tumorigenesis in osteosarcoma via Wnt/beta-catenin signaling pathway [J]. Int J Biochem Cell Biol, 2019, 111(6): 42-51.19 Li Y, Zhang T, Zhang YH, et al. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma [J]. Cancer Sci, 2018, 109(10): 3093-3104.20 Feng YB, Xiao-Po L, Xiao-Li L, et al. LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma [J]. Open Med, 2016, 11(1): 163-167.21 Xie CH, Cao YM, Huang Y, et al. Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression [J]. Tumor Biology, 2016, 37(11): 15031-15041.22 Li H, Tian GF, Tian FP, et al. Long non-coding RNA TUG1 promotes osteosarcoma cell proliferation and invasion through inhibition of microRNA-212-3p expression [J]. Exp Ther Med, 2018, 16(2): 779-787.23 Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function [J]. Nat Rev Genet, 2016, 17(1): 47-62.24 Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development [J]. Nat Rev Genet, 2014, 15(1): 7-21.25 Bolha L, Ravnik-Glavac M, Glavac D. Long noncoding RNAs as biomarkers in cancer [J]. Dis Markers, 2017,5: 7243968.26 Smolle MA, Pichler M. The Role of Long Non-Coding RNAs in Osteosarcoma[J]. Noncoding RNA, 2018,4(1):7.

相似文献/References:

[1]张洁,黄辉,王俊国,等.hBMP-2基因改良修饰骨髓间充质干细胞和人脐血间充质干细胞研究[J].中华老年骨科与康复电子杂志,2019,(02):82.[doi:10.3877/cma.j.issn.2096-0263.2019.02.004]
 Zhang Jie,Huang Hui,Wang Junguo,et al.Research on bone marrow derived-mesenchymal stem cells and human umbilical cord blood derived-mesenchymal stem cells modified with the gene of human bone morphogenetic protein-2[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2019,(01):82.[doi:10.3877/cma.j.issn.2096-0263.2019.02.004]

备注/Memo

备注/Memo:
贵州省卫生计生委基金项目(gzwjkj2017-1-031)
更新日期/Last Update: 2020-07-07